

DUROLANE Corporate Brand Guidelines

Implementing the DUROLANE brand in communications
Updated September, 2019

DUROLANE[®]
hyaluronic acid, stabilized single injection

Table of Content

About This Guide	2
About DUROLANE	3
Logo	4
Size	5
Tagline & Positioning	6
White Space	7
Usage with Company Logo	8
Approved Variations	9
Color	10
Typography	11
Photography	13

Graphic Dust	14
DUROLANE.com	15
Primary/Secondary Colors	16
Layout	17
Typography	18
Photography	19
Footer/Indications.	20
Indications for Use	21
Contact Information	24
Trademark Usage	25

About This Guide

2

It Takes a Village to Build a Brand, and That Village Is Us

This document is designed to give you clarity and guidance when applying or interacting with the DUROLANE brand. Here, you will discover what the brand is and how we integrate it into our work.

The information you will find here helps us talk about DUROLANE in a unified voice to many audiences. It's more than just how to size the logo or select the right color. It frames the way we shape beliefs and behaviors among healthcare providers, patients, and other stakeholders.

About DUROLANE

3

Also Known as: DUROLANE's Online Dating Profile

The “elevator pitch”

DUROLANE is a single-injection treatment designed to provide powerful and long-lasting relief from knee pain caused by osteoarthritis. It was created with a unique stabilizing technology, so it stays in the joint longer for powerful relief from a single injection.

Brand personality

Brand personality derives from characteristics that describe the brand as if it were a person. What is our brand like? How does our brand make our audiences feel? The DUROLANE brand personality is that of an inspired leader, someone who is forward thinking yet relatable, and:

- Powerful
- Confident
- Current
- Innovative
- Active, energetic
- Happy

DUROLANE key messages

1. Powerful and long-lasting pain relief¹⁻⁵
2. More clinical studies than any other single-injection HA knee therapy
3. Greater reduction in knee pain vs. Synvisc-One^{®1}
4. Longer-lasting knee pain relief vs. steroid²
5. Clinically equivalent performance to five-injection^{3,4}
6. DUROLANE significantly improved Quality of Life⁵
7. A history of safe use

1. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. *J Arthritis*. 2013;2(1):108. doi:10.4172/2167-7921.1000108. 2. Leighton R, Åkemark C, Therrien R, et al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. *Osteoarthritis Cartilage*. 2014;22(1):17-25. 3. Zhang H, Zhang K, Zhang X, et al. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. *Arthritis Res Ther*. 2015;17:51. doi: 10.1186/s13075-015-0557-x. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017. 5. Ågerup B, Berg P, Åkemark C. Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. *BioDrugs*. 2005;19(1):23-30. 5. Krockner D, Matziolis G, Tuischer J, et al. Reduction of arthrosis associated knee pain through a single intraarticular injection of synthetic hyaluronic acid. *Rheumatol*. 2006;65(4):327-31.

Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.

Logo

4

Two Things Best Left Alone: Sleeping Babies and the DUROLANE Logo

The DUROLANE logo is the face of the product, making it a valuable corporate asset. As such, it is imperative that you consistently use the logo in the approved forms.

All elements of the logo—from the font to the colors—were carefully selected to create a clear identity that can be differentiated from competitors. The DUROLANE logo is simple, flexible (within guidelines), and appropriate for our audiences. The Brand Guidelines include instructions about how to use the logo on sales materials, websites, internal documents, promotional items, etc.

All uses of the DUROLANE logo must be approved by the Bioventus Brand Team (contact Creative Services).

DUROLANE[®]
hyaluronic acid, stabilized single injection

~~**DUROLANE[®]**
hyaluronic acid, stabilized single injection~~

~~**DUROLANE[®]**
hyaluronic acid, stabilized single injection~~

~~**DUROLA**
hyaluronic acid, stabilized single~~

Logo Size

5

A Logo That's Too Small Is Like Shoes That Are Too Tight

While it is OK to change the size of the logo to suit your needs, there is a point at which the logo becomes illegible and thus ineffective. When reproducing the logo, always adhere to these minimum size standards.

With tagline

The DUROLANE logo should not be reproduced smaller than 1-inch (2.54 cm) wide for printing materials and 96 pixels for electronic applications.

Without tagline*

The DUROLANE logo should not be reproduced smaller than 1.5 inches (3.8 cm) wide for printing materials and 144 pixels for electronic applications.

*The only time the logo should appear without the tagline is when the logo needs to be smaller than 144 pixels



Logo Tagline & Positioning


6

Like Any Great Couple, the Tagline and Logo Make Each Other Better

The DUROLANE logo tagline is:

hyaluronic acid, stabilized single injection

The tagline should appear with the DUROLANE logo on all corporate communications. (The only time the logo should appear without the tagline is when the logo needs to be smaller than 144 pixels.) The tagline is written all lowercase. For alignment purposes, the tagline should always begin at the left edge of the letter “D” and end on the right edge of the letter “E.”



Logo White Space

7

Like an Invisible Fence for the Logo

The DUROLANE logo sits on a white background. The margin around the logo should equal the height and width of the letter “O” from brand name on every edge. This margin prevents other design elements from coming into contact with the logo. You should always apply this standard when resizing the logo. The result is a clean, attractive space around the logo.

Clear Space — Durolane Logo With Tagline



Clear Space — Durolane Logo Minus Tagline



Logo

Usage with Company Logo

8


Competition Is Great—Just Not Against Ourselves

When the DUROLANE logo appears with a company logo, the DUROLANE logo should be 125% of the company logo size. If this causes the Bioventus logo to be smaller than its minimum size (1 inch/96 pixels), the logos must be separated:

- The DUROLANE logo should occupy the upper position of the page
- The Bioventus logo should occupy the lower-right position of the page

When used with a product logo, the white space above the Bioventus logo doubles, ensuring that both logos have adequate white space.

It is preferred that the DUROLANE logo and the Bioventus logo appear separately.



Logo

Approved Variations

Just Like TV: Black and White Is an Option, But Everyone Prefers Color

The primary DUROLANE logo is the CMYK version: Pantone 2627c and process cyan. In situations that prohibit using the 2-color version, the logo may be used in all black or reversed out to white. A grayscale version is also acceptable on all black-and-white communications (faxes, forms, and legal documents). No other logo variations should be used.

Note: An effort should be made to use the primary logo in favor of any secondary logos.

Primary Logo



Secondary Logos



Color

Primary/Secondary Colors

10

A Computer Can Display 16 Million Colors. You Can Display 4.

Consistent use of color across all media is essential to the integrity of the DUROLANE logo. The colors shown here are the approved primary color variations for print (CMYK) and web (RGB) formats. No other color specifications should be used. Do not change color tints or shades of the logo elements, regardless of whether or not they are within the DUROLANE color palette.

Primary



PRINT

PMS 2627C
CMYK 77 100 0 31

WEB

RGB 73 23 109
HEX #49176D



PRINT

PMS CYAN
CMYK 100 0 0 0

WEB

RGB 0 174 239
HEX #00aeef

Secondary



PRINT

PMS Cool Gray 9
CMYK 56 46 44 10

WEB

RGB 118 119 123
HEX #76777B



PRINT

PMS Black
CMYK 0 0 0 100

WEB

RGB 0 0 0
HEX #000000

Typography

11

If It's Called a Type Face, are Century Gothic and Arial Considered Facial Expressions?

Typography contributes to our overall brand identity; it's another element of our personality that comes through when we express ideas, products, and our brand. DUROLANE uses the following typefaces:

- **Print:** Century Gothic and Arial
- **Web:** Century Gothic and Arial
- **PowerPoint:** Century Gothic and Calibri (replaces Arial in all corporate presentations)

Headline

Subhead

Body copy body copy

Headline

Subhead

Body copy body copy

Headline

Subhead

Body copy body copy

~~Headline~~

~~Subhead~~

~~Body copy body copy~~

~~Headline~~

~~Subhead~~

~~Body copy body copy~~

~~Headline~~

~~Subhead~~

~~Body copy body copy~~

Century Gothic should be used for all headlines and section headers and can be used for callouts. When used as a headline, it should be Pantone 2627 or reversed out of a bar of one of the primary colors. It should always be typeset in Century Gothic Regular. Bold, Italic, and Bold Italic are permitted to add emphasis only. For instance, a callout would be typeset in Century Gothic Italic.

ABCDEFGHIJKLMNOPQRSTUVWXYZ
abcdefghijklmnopqrstuvwxyz
1234567890

Arial should be used for all subheads, tables, and body copy. It can be used for callouts as well. When used as a subhead, it should be either Pantone 2627 Black, or Cool Grey 9. It should always be differentiated from the headline by size and color. Body copy can be set in either Black or Cool Grey 9.

ABCDEFGHIJKLMNOPQRSTUVWXYZ
abcdefghijklmnopqrstuvwxyz
1234567890

Note: For black-and-white pieces **only**, headlines should be 100 percent black, subheads and body copy should be 75 percent black.

Proper Formatting Is Always on Your To-Do List

Lists (bullets)

Lists should be indented 0.125" from the margin and distinguished by either a bullet or a number. Type should begin one character space from the bullet or number. The space between list items must be 1½ the amount of the leading used. Sublists should be distinguished with either a hyphen or lowercase alphabet letters. When a list item requires more than one line of copy, the leading should hold the list item together as a single entity.

Note: Bullets should match font color (Black or Cool Grey 9)

- This is a correct usage of a bullet
- This is a correct usage of a bullet that requires 2 lines of copy
 - This is a correct usage of a sub-bullet
 - This is a correct usage of a sub-bullet
- ~~• This is an incorrect usage of a bullet~~
- ~~• This is an incorrect usage of a bullet that requires 2 lines of copy
 - ~~- This is an incorrect usage of a sub-bullet~~
 - ~~- This is an incorrect usage of a sub-bullet~~~~

Call-Outs

Distinguish callouts from the surrounding copy by providing adequate white space. Callouts should be at least 4 points larger than the point size used for the body copy. They can appear in either Arial or Century Gothic, but they must be consistent throughout the piece. For callouts, you can use any of the primary or secondary color palettes.

“Bioventus products help patients heal quickly and safely.”

Photography

13

A Picture is Worth 1,000 Words. Unless It's on iStock, Where It's Worth about \$30.

Photography associated with DUROLANE should meet these criteria:

Use ordinary people: The subjects should not be movie-star beautiful, nor should they be raggedy.

Ensure they are adults: No one under 20. DUROLANE target audience is between 45 and 65.

Show people being active: They should be engaging in sports or recreation, or moving in an everyday capacity.


Focus on one: Images should draw attention to one person, even if multiple people are shown in the photo.

Don't worry, be happy: Images should capture people living happy, stress-free lives.

Stay warm: Show warm colors with effective contrast in lights and darks.

If you need additional stock photographs, such images should be submitted to the Brand Team for approval prior to purchasing (contact Creative Services).

Sample Images



Graphic Dust

14

When You Want Poetry in Motion, but You Don't Have a Poet

Solid Colors

When using the graphic dust as a solid color, always use DUROLANE purple or cyan from the color palette. Never use solid white or black unless as a transparency.

White

Over a light color, the basic blending mode should be 100% soft light. Over a dark color, the basic blending mode should be 100% overlay.

Black

A black spray can be used, but only on black-and-white projects. It must be screened back no more than 30%.

Gradation

Gradation should always be a DUROLANE cyan to DUROLANE purple.


Correct Gradation



Bioventus Purple




Bioventus Cyan / DUROLANE



Soft Light 100%



Overlay 100%




30%




40%



Incorrect usage



Incorrect usage



The purpose of the DUROLANE.com guide is to define accepted design standards for the DUROLANE website. This guide provides you with an understanding of the basic design principles for the website, enabling you to treat designs in a consistent manner throughout every application.

Conventions:

- All measurements are in pixels, the standard and most accurate measurement for digital interfaces
- All colors are listed as HEX values, the standard for digital interfaces



4 Colors—but 15 Possible Combinations

Consistent use of color across all media is essential to the integrity of DUROLANE. The colors shown here are the approved primary color variations for web (RGB) formats. No other color specifications should be used.

Primary



PRINT

PMS 2627C
CMYK 77 100 0 31

WEB

RGB 73 23 109
HEX #49176D



PRINT

PMS CYAN
CMYK 100 0 0 0

WEB

RGB 0 174 239
HEX #00aeef

Secondary



PRINT

PMS Cool Gray 9
CMYK 56 46 44 10

WEB

RGB 118 119 123
HEX #76777B



PRINT

PMS Black
CMYK 0 0 0 100

WEB

RGB 0 0 0
HEX #000000

The website is Responsive

Each section should be laid out in 1-4 evenly spaced columns

Each section routes between a white background and a colored background sections. When two white sections align next to one other, they should be separated with a colored call out.

Desktop



Mobile device/tablets



Fonts

Century Gothic and Arial

Page Headers

Century Gothic, Sentence case, white and placed over a colored background image. One or more words should be emphasized by increased size and bold.

Subheaders

Century Gothic, Sentence case, Purple when over white

Body Copy

Arial, Gray when over white

Reference Numbers

Purple when over white

Hyperlinks

Purple when over white; underlined

Page Headers

Reference Numbers

Body Copy

Hyperlink

Subhead



Physician

Not counting call-outs a majority of the images need to be geared more to the Medical field.



Patient

These images should be geared to patient and there everyday activities.



The footer needs to be placed on all pages and not changed except for the copyright date.

Indications for Use

Direct Markets - United States & Canada

21

United States

Summary of Indications for Use:

DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.

Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site.

DUROLANE has not been tested in pregnant or lactating women, or children.

Full prescribing information can be found in product labeling, at DUROLANE.com, or by contacting Bioventus Customer Service at 1-800-836-4080.

Canada - English

Summary of Indications for Use:

DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been licenced for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

DUROLANE SJ (1 mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure. There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in children or pregnant or lactating women.

Risks can include transient pain, swelling and/or stiffness at the injection site. Full prescribing information can be found in product labeling, or at DUROLANE.com.

Full prescribing information can be found in product labeling, or at DUROLANE.com.

Canada - French

Résumé des indications d'utilisation

DUROLANE (3 mL): Traitement symptomatique de l'arthrose du genou ou de la hanche d'intensité légère à modérée. En outre, DUROLANE a été approuvé pour le traitement symptomatique associé aux douleurs arthrosiques légères à modérées touchant les chevilles, les doigts et les orteils.

DUROLANE SJ (1 mL): Traitement symptomatique associé aux douleurs arthrosiques légères à modérées touchant les chevilles, les doigts et les orteils.

DUROLANE et DUROLANE SJ sont également tous deux indiqués pour soulager les douleurs ressenties après une arthroscopie, en présence d'arthrose ou après une réparation chirurgicale générale, ou dans les trois mois suivant l'intervention.

Il n'existe aucune contre-indication connue. Ne pas utiliser DUROLANE si vous présentez une infection ou une affection cutanée au niveau du site d'injection. DUROLANE n'a pas été évalué chez la femme enceinte ou allaitante ni chez l'enfant. Les risques peuvent inclure : douleur passagère, gonflement et/ou raideur au niveau du site d'injection.

Les renseignements thérapeutiques complets peuvent être consultés dans la notice du produit sur le site www.DUROLANE.com.

Indications for Use

Direct Markets - European Union

22

English

Summary of Indications for Use:

DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been licenced for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

DUROLANE SJ (1 mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure. There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in children or pregnant or lactating women.

Risks can include transient pain, swelling and/or stiffness at the injection site. Full prescribing information can be found in product labeling, or at DUROLANE.com.

Full prescribing information can be found in product labeling, or at DUROLANE.com.

Dutch (the Netherlands)

Résumé des indications d'utilisation

DUROLANE (3 mL): Traitement symptomatique de l'arthrose du genou ou de la hanche d'intensité légère à modérée. En outre, DUROLANE a été approuvé pour le traitement symptomatique associé aux douleurs arthrosiques légères à modérées touchant les chevilles, les doigts et les orteils.

DUROLANE SJ (1 mL): Traitement symptomatique associé aux douleurs arthrosiques légères à modérées touchant les chevilles, les doigts et les orteils.

DUROLANE et DUROLANE SJ sont également tous deux indiqués pour soulager les douleurs ressenties après une arthroscopie, en présence d'arthrose ou après une réparation chirurgicale générale, ou dans les trois mois suivant l'intervention. Il n'existe aucune contre-indication connue. Ne pas utiliser DUROLANE si vous présentez une infection ou une affection cutanée au niveau du site d'injection. DUROLANE n'a pas été évalué chez la femme enceinte ou allaitante ni chez l'enfant. Les risques peuvent inclure : douleur passagère, gonflement et/ou raideur au niveau du site d'injection.

Les renseignements thérapeutiques complets peuvent être consultés dans la notice du produit sur le site www.DUROLANE.com.

German (Germany)

Indikationen

DUROLANE (3 mL): Symptomatische Behandlung von leichter bis mittelschwerer Arthrose im Knie oder Hüftgelenk. Darüber hinaus ist DUROLANE in der EU für die symptomatische Behandlung im Zusammenhang mit leichten bis mittelschweren Arthroseschmerzen in Knöchel-, Schulter-, Ellenbogen-, Hand-, Finger- und Zehengelenken zugelassen.

DUROLANE SJ (1 mL): Symptomatische Behandlung im Zusammenhang mit leichten bis mittelschweren Arthroseschmerzen in Knöchel-, Ellenbogen-, Hand-, Finger- und Zehengelenken. Sowohl DUROLANE als auch DUROLANE SJ sind ebenfalls für Schmerzen nach Gelenkarthroskopien bei Vorliegen von Arthrose innerhalb von drei Monaten nach dem Eingriff indiziert.

Es sind keine Gegenanzeigen bekannt.

Sie sollten DUROLANE nicht anwenden, wenn Sie Infektionen oder Hauterkrankungen an der Einstichstelle haben. DUROLANE wurde nicht zur Anwendung bei schwangeren oder stillenden Frauen oder bei Kindern getestet.

Zu den Risiken zählen vorübergehende Schmerzen, Schwellungen und/oder Verhärtungen an der Einstichstelle. Vollständige Informationen zur Verordnung finden Sie auf der Produktetikettierung, oder unter www.DUROLANE.com.

Polish (Poland)

Streszczenie wskazań użycia

DUROLANE (3 mL): leczenie objawowe łagodnej i umiarkowanej choroby zwyrodnieniowej stawu kolanowego i biodrowego. Preparat DUROLANE został zatwierdzony na terenie UE do leczenia objawowego łagodnego i umiarkowanego bólu związanego z chorobą zwyrodnieniową stawu skokowego, barkowego, łokciowego, nadgarstkowego oraz stawów międzypaliczkowych palców rąk, nóg.

DUROLANE SJ (1 mL): leczenie objawowe łagodnego i umiarkowanego bólu związanego z chorobą zwyrodnieniową stawu skokowego, łokciowego, nadgarstkowego oraz stawów międzypaliczkowych palców rąk, nóg.

Zarówno preparat DUROLANE, jak i preparat DUROLANE SJ są także wskazane w leczeniu bólu po artroskopii w obecności choroby zwyrodnieniowej stawu w ciągu 3 miesięcy po zabiegu. Brak znanych przeciwwskazań.

Preparatu DUROLANE nie należy stosować w przypadku zakażeń lub choroby skóry w miejscu iniekcji. Preparatu DUROLANE nie badano u kobiet w ciąży i karmiących piersią ani dzieci. Do zagrożeń mogą należeć: przemijający ból, obrzęk i/lub sztywność w miejscu iniekcji. Pełną informację dotyczącą produktu można znaleźć w ulotce dołączonej do opakowania, na stronie www.DUROLANE.com.

Indications for Use

Indirect Markets - Argentina, Australia, Brazil, Chile, Colombia, EU, Hong Kong, Indonesia, India, Jordan, Kingdom of Saudi Arabia, New Zealand, Mexico, Russia, Switzerland, Taiwan, Turkey, United Arab Emirates

English

Summary of Indications for Use

DUROLANE (3 mL):

- Argentina, Australia,[†] Brazil, Chile, Colombia, EU,[†] Hong Kong, Indonesia, India, Jordan, Kingdom of Saudi Arabia, New Zealand,[†] Russia, Switzerland,[†] Turkey,[†] United Arab Emirates: Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in Australia, New Zealand and EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

- Mexico: Symptomatic treatment of mild to moderate knee osteoarthritis.

- Taiwan: Treatment of pain in OA of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

DUROLANE SJ (1 mL):

- Australia,[†] EU,[†] New Zealand,[†] Russia,[†] Switzerland,[†] Turkey[†]: Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.

There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Full prescribing information can be found in product labeling, or at DUROLANE.com.

[†]Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

Contact Information

Direct & Indirect Markets

24

Direct Market United States	Bioventus LLC. 4721 Emperor Boulevard Suite 100 Durham, NC 27703 Customer Service T: 1-800-836-4080 E: ctservicescenter@bioventusglobal.com
Direct Market Canada English, French	Bioventus Canada ULC 2476 Argentia Road, Suite 100 Mississauga, ON L5N 6M1 Canada Customer Service T: 1-855-771-0606 E: Canada.Durolane@bioventusglobal.com
Direct Market European Union English (United Kingdom, Ireland)	Bioventus Coöperatief U.A. Taurusavenue 31 2132 LS Hoofddorp The Netherlands Customer Care T (UK): 0800 05 16 384 T (IR): 1800 552 197 E: customercare-international@bioventusglobal.com
Direct Market European Union Dutch (the Netherlands)	Bioventus Coöperatief U.A. Taurusavenue 31 2132 LS Hoofddorp Nederland Customer Care T: 0800 0599 E: customercare-international@bioventusglobal.com

Direct Market European Union German (Germany)	Bioventus Germany GmbH Paul Gerhardt-Allee 50 81245 München Deutschland Customer Care T: 0800 1833735 (Kostenfrei) F: +49 (0)32 22 10 94 056 E: customercare-international@bioventusglobal.com
Direct Market European Union Polish (Poland)	Bioventus Poland Sp. z o.o. ul. Grzybowska 2/29 00-131 Warsaw Poland Customer Care T: 00800 3111 376 E: customercare-international@bioventusglobal.com
Indirect Markets Argentina, Australia, Brazil, Chile, Colombia, EU, Hong Kong, Indonesia, India, Jordan, Kingdom of Saudi Arabia, New Zealand, Mexico, Russia, Switzerland, Taiwan, Turkey, United Arab Emirates	Bioventus Coöperatief U.A. Taurusavenue 31 2132 LS Hoofddorp The Netherlands Customer Care T: 00800 02 04 06 08 E: customercare-international@bioventusglobal.com

DUROLANE Trademark Usage

DUROLANE®

The first reference to DUROLANE within a document should be appropriately trademarked with the ® symbol (superscripted). Additional uses of the product name do not need the registered trademark symbol. Notification of the mark should be written on the document (or for a slide deck, on the slide containing the ®), and should read:

- DUROLANE is a registered trademark of Bioventus LLC.

When other products, technologies, or trade names are included in a document, these should be appropriately designated. NASHA should include the ® symbol and notification. Notification of the mark should be written on the document (or for a slide deck, on the slide containing the ®), and should read:

- DUROLANE is a registered trademark of Bioventus LLC.
- NASHA is a registered trademark of Nestlé Skin Health S.A.

This same convention should be used for competitive products.

English	DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.
Dutch	DUROLANE, Bioventus en het logo van Bioventus zijn geregistreerde handelsmerken van Bioventus LLC. NASHA is een geregistreerd handelsmerk van Nestlé Skin Health S.A.
German	DUROLANE, Bioventus und das Bioventus Logo sind eingetragene Warenzeichen von Bioventus LLC. NASHA ist eine eingetragene Marke von Nestlé Skin Health S.A.
Polish	DUROLANE, Bioventus i logo Bioventus są zastrzeżonymi znakami towarowymi firmy Bioventus LLC. NASHA to zarejestrowany znak towarowy firmy Nestlé Skin Health S.A.
French	DUROLANE, Bioventus et le logo Bioventus sont des marques de commerce déposée de Bioventus LLC. NASHA est une marque de commerce déposée de Nestlé Skin Health S.A.